Antengene (HKG:6996) obtained new drug application approval for three indications of XPOVIO (selinexor) from the Indonesia National Agency of Drug and Food Control, a Wednesday Hong Kong bourse filing said.
The indications include a combination with bortezomib and dexamethasone used for the treatment of multiple myeloma in adult patients, a combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma, and as a monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adult patients.
Multiple myeloma is a cancer related to the white blood cells called plasma cells, while diffuse large B-cell lymphoma is cancer related to the white blood cells called lymphocytes.
Shares of the company were up nearly 11% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。